ReviewAmerican journal of preventive cardiology2025
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis.
Review in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Intervening Early in the Cardiovascular-Kidney-Metabolic Syndrome: Expert Recommendations from the United Arab Emirates on the Management of Prediabetes.Vascular health and risk management · 2026Guideline
- Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Empagliflozin's Effects on Carotid Ultrasound Parameters in Type 2 Diabetes Patients Post-ST-Elevation Myocardial Infarction: A Randomized Controlled Trial.Iranian journal of medical sciences · 2026Trial
- Patient-Level Multidimensional Response Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Sex Differences in Ventricular Antiarrhythmic Effect of Sodium-Glucose Cotransporter 2 Inhibitor.JACC. Asia · 2026Article
- Optimal Medical Therapy Targeting Metabolic Status for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Review
- Beyond traditional lipid markers: low-density lipoprotein cholesterol with apolipoprotein B ratio - a novel biomarker for sarcopenia?Archives of medical science : AMS · 2026Article
- Role of Sodium-Glucose Transport Protein-2 Inhibitors in Renal Protection: A Narrative Review from the Cardiovascular-Kidney-Metabolic Interconnection.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a promising therapeutic class in cardiovascular disease. This review synthesizes clinical and preclinical evidence on their effects on atherosclerosis, arterial stiffness and related conditions, including dyslipidemia, coronary artery disease, peripheral artery disease, and stroke. The atheroprotective advantages of SGLT2i are attributed to multiple mechanisms, including modulation of inflammatory pathways, improvements in vascular function, and reductions in oxidative stress, in addition to enhanced glycemic control, weight reduction, antihypertensive, and antifibrotic effects. Recent studies highlight their minimal adverse effects and compatibility for combination therapies, further expanding their clinical applications. SGLT2i have redefined the landscape of cardiovascular treatment through their extensive range of benefits, offering significant promise in optimizing outcomes for patients with atherosclerotic cardiovascular disease. By setting new standards of care and maintaining a favorable safety profile, these agents continue to advance the paradigm of cardiovascular disease management. While definitive conclusions require further investigation, SGLT2i have become serious contenders in the argument for antiatherosclerotic effects, with accumulating evidence suggesting their positive influence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.